链接:https://aacrjournals.org/cancerres/article/84/6_Supplement/1158/737448/Abstract-1158-Spatially-resolved-cell-profiling?searchresult=1 8.题目:Single-cell spatial landscape of the mutation-specific human lung tumor immune microenvironment 研究机构:Justus Liebig University 类型:肺癌 PCF抗体数量:42-pl...
a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that an abstract has been accepted for presentation at the American Association for Cancer Re...
Abstract Book of ESMO Breast Cancer 2024, Berlin, Germany, 15-17 May 2024Publication of this Abstract book is supported by the European Society for Medical Oncology May 2024 Previous vol/issue Next vol/issue Actions for selected articles
Abstract7588:DiscoveryofNSP-5033:AnovelandpotentPARP7/12dual诺沃斯达药业有限公 1AACR2024 inhibitor司 Abstract4535:JAB-26766:Asmall-molecule,orallybioavailablePARP7北京加科思新药研发 2AACR2024 inhibitorwithhighpotencyandselectivity有限公司 AbstractB072:InductionofPARP7createsavulnerabilityforgrowthAACR_APCRUnivers...
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from
编者按:随着肿瘤治疗的不断进步,免疫检查点抑制剂(ICIs)已成为多种肿瘤治疗中不可或缺的一环。在2024 CSCO指南会免疫治疗专场,山东第一医科大学第一附属医院王俊教授分享解读了2024版CSCO《免疫检查点抑制剂临床应用指南》上部分主要章节...
LONDON, UK, 10 OCT 2024,Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments, today announced that the Company will present new preclinical data on two breakthroughs in the pre|CISION™ platformin poster sessions at the2024EORTC-NCI-AACR Symp...
2023ESMO abstract book ESMO 2023 Abstract全文.pdf 2024.v1 NCCN临床实践指南:头颈癌 2024.v1 NCCN临床实践指南:头颈部肿瘤.pdf 023.v4 NCCN临床实践指南:前列腺癌 2023.v4 NCCN临床实践指南:前列腺癌.pdf 2024.v2 NCCN临床实践指南:遗传/家族高风险评估-乳腺癌,卵巢癌和胰腺癌 2024.v2 NCCN临床实践指南:遗传...
AACR2024 诺沃斯达药业有限公 司 2 Abstract4535:JAB-26766:Asmall-molecule,orallybioavailablePARP7 inhibitorwithhighpotencyandselectivity AACR2024 北京加科思新药研发 有限公司 3 AbstractB072:InductionofPARP7createsavulnerabilityforgrowth inhibitionbyRBN2397inprostatecancercells ...
(Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, will present data on its two clinical stage programs, 23ME-01473 targeting ULBP6, and 23ME-00610 targeting CD200R1, at the Am...